Skip to main content

Table 3 Twelve-month clinical progression and psychotropic drug utilisation for patients with anxiety and depressive disorders by type of medical practicea (N = 710)

From: Homeopathic medical practice for anxiety and depression in primary care: the EPI3 cohort study

 

GP-Mx vs GP-CM

GP-Ho vs GP-CM

ORc [95 % CI]

ORc [95 % CI]

(p value)

(p value)

Clinical improvement (HADS score <9b)

 All patientsd

1.49 [0.89–2.50]

1.70 [1.00–2.87]

(0.13)

(0.05)

 HADS ≥12 at inclusion

1.52 [0.69–3.34]

1.70 [0.81–3.55]

(0.30)

(0.16)

 HADS <12 at inclusion

1.34 [0.66–2.72]

1.61 [0.77–3.38]

(0.42)

(0.21)

Psychotropic drug useb

 All patientsd

0.62 [0.41–0.94]

0.29 [0.19–0.44]

(0.02)

(<0.001)

 HADS ≥12 at inclusion

0.63 [0.38–1.07]

0.29 [0.18–0.48]

(0.08)

(<0.001)

 HADS <12 at inclusion

0.65 [0.32–1.31]

0.33 [0.15–0.66]

(0.23)

(0.003)

  1. aType of medical practice according to physicians’ prescribing preferences: GP-CM conventional medicine (group of reference); GP-Mx mixed, conventional and homeopathic practice; GP-Ho registered homeopathic physicians
  2. b HADS score less than 9 at the 12-month follow-up; any psychotropic drug use declared in the 12-month follow-up
  3. cOdds ratios and 95 % confidence intervals obtained from GEE models adjusted for propensity score including all variables in Tables 1 and 2
  4. dOdds ratios for all patients may not lie between those obtained for the two severity subgroups as they result from separate multivariate analyses and were shown to have wide confidence intervals